521 - Rate of discontinuation and reasons for discontinuation of intravesical onabotulinum toxin A treatment in patients with symptomatic Overactive Bladder (OAB)
| Autor: | Scrimgeour, G., Aleksejeva, K., Axell, R., Yasmin, H., Nadeem, M., Pakzad, M.H., Hamid, R., Ockrim, J.L., Greenwell, T.J. |
|---|---|
| Zdroj: | In European Urology Open Science July 2020 19 Supplement 2:e810-e811 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|